ANALYSIS OF MUTATIONS OF TUBERCULOUS MYCOBACTERIA DEFINING DRUG RESISTANCE IN HIV POSITIVE AND HIV NEGATIVE TUBERCULOSIS PATIENTS WITHOUT PRIOR HISTORY OF TREATMENT IN SVERDLOVSK REGION

Goal of the study: to identify profile of mutations of tuberculous mycobacteria responsible for resistance to anti-tuberculosis drugs in HIV positive and HIV negative tuberculosis patients without prior history of treatment.

Materials and methods. 165 strains of tuberculous mycobacteria from HIV positive patients and 166 strains of tuberculous mycobacteria from HIV negative patients were studied in Sverdlovsk Region (TB Dispensary, Yekaterinburg). Mutations in genes were identified using microchips of TB-BIOCHIP® and TB-BIOCHIP®-2 in compliance with the manufacturer's guidelines (OOO Biochip-IMB, Moscow).

Results. It was observed that 85/165 (51.52%) strains isolated from HIV positive tuberculosis patients and 58/166 (34.94%) strains isolated from tuberculosis patients not associated with HIV possessed MDR genotype (p < 0.01). The majority of MDR strains had mutations in the 531th codon of rpoB (Ser→Leu) and 315th codon of katG (Ser→Thr) (64/85, 75.29% and 38/58, 65.52% respective the groups), resulting in the high level of resistance to rifampicin and isoniazid. Each group also had approximately equal ratio (11/165, 6.67% and 12/166, 7.23% respective the groups) of strains with genomic mutations defining the resistance to isoniazid, rifampicin and fluoruquinolones. No confident difference was found in mutation patterns of genome of tuberculous mycobacteria isolated from HIV positive and HIV negative tuberculosis patients. 

1. Нечаева О. Б. Ситуация по туберкулезу в России в 2014 г. [Электронный ресурс]. URL: http://www.mednet.ru/images/stories/files/CMT/ 2014tb.pdf

2. Подгаева В. А. Эпидемическая ситуация по туберкулезу и деятельность противотуберкулезной службы на Урале в 2014 г. / Под ред. С. Н. Скорнякова. - Екатеринбург, 2015. - 425 с.

3. Andrews J. R., Shah N. S., Weissman D. et al. Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community // PLoS One. - 2010. - Vol. 5, № 12. - Р. e15735.

4. Bodmer T., Zurcher G., Imboden P. et al. Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis // J. Antimicrob. Chemother. - 1995. - Vol. 35. - P. 345-348.

5. Casali N., Nikolayevskyy V., Balabanova Y. et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population // Nat. Genet. - 2014. - Vol. 46, № 3. - P. 279-286.

6. Gandhi N. R., Moll A., Sturm A. W. et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa // Lancet. - 2006. - Vol. 368. - P. 1575-1580.

7. Pym A. S., Saint-Joanis B., Cole S. T. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans // Infect. Immun. - 2002. - Vol. 70. - P. 4955-4960.

8. Suchindran S., Brouwer E. S., Van Rie A. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review // PLoS One. - 2009. - Vol. 4, № 5. - Р. e5561.

9. Zhang Y., Heym B., Allen B. et al. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis // Nature. - 1992. - Vol. 358. - P. 591-593.

10. Zhang Y., Yew W. W. Mechanisms of drug resistance in Mycobacterium tuberculosis // Int. J. Tuberc. Lung Dis. - 2009. - Vol. 13, № 11. - P. 1320-1330.